Developer docs
API playgroundTry for free, no card

Search company profiles

Celmatix

Full company profile

uuid0000cvi

Namestring
Celmatix
Legal namestring
Celmatix Inc.
Websiteurl
celmatix.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Celmatix is a US-based, preclinical-stage women's health biotechnology company founded in 2009 and headquartered in New York City. It develops novel therapeutics targeting ovarian biology and female reproductive health across four primary indications: infertility, endometriosis, polycystic ovary syndrome (PCOS), and ovarian aging. Its pipeline centers on first-in-class candidates including an oral follicle-stimulating hormone (FSH) receptor agonist for fertility, a Jun N-terminal kinase (JNK) inhibitor for endometriosis pain and inflammation, anti-Müllerian hormone (AMH)-targeting antibodies for ovarian function, and peripherally restricted melatonin receptor agonists for PCOS and related conditions. Discovery leverages the DNA-Encoded Chemistry Technology (DEC-Tec) platform housed at Baylor College of Medicine's Center for Drug Discovery and is informed by the largest published genetic dataset on endometriosis, assembled with the University of Oxford and 24 collaborating institutions.

Celmatix operates as a B2B asset-development biotech rather than a commercial product company. Its revenue model is built on licensing deals, asset sales, and milestone payments from pharmaceutical partners, supplemented by non-dilutive research grants. In March 2026, Gedeon Richter acquired Celmatix's discovery portfolio — encompassing the oral FSH receptor agonist, JNK inhibitor, and AMH antibody programs — in exchange for upfront and milestone payments; Celmatix retained certain residual programs and continues to operate. The company also has a free consumer-facing digital tool, MyFertivity Compass, that provides fertility-related analytics without disclosed monetization. Headcount sits in the 101–250 range, consistent with a preclinical biotech sustaining multiple discovery programs alongside an academic and pharma partnership network that includes Aché Laboratórios, Evotec, and Baylor College of Medicine.

Short descriptiontext

Celmatix is a preclinical-stage women's health biotech developing first-in-class therapeutics for infertility, endometriosis, PCOS, and ovarian aging using the DEC-Tec discovery platform, monetizing its pipeline through licensing, asset sales, and grants.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
women's health therapeutics, fertility drug development, reproductive medicine biotech, endometriosis treatment, ovarian biology research
Industry1 code
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Women's Health Therapeutics / Reproductive Health Drug Discovery
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and asset sales
TypeLicensing Royalties
Description

Celmatix generates revenue through licensing agreements and asset sales to pharmaceutical companies. In March 2026, Gedeon Richter acquired Celmatix's women's health discovery portfolio including upfront and milestone payments as development progresses.

celmatix.com
2Research funding and grants
TypeProfessional Services
Description

Non-dilutive funding from government agencies such as ARPA-H to support early-stage research efforts in women's health therapeutics.

businesswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Celmatix is a preclinical-stage women's health biotech that discovers and develops novel therapeutics targeting ovarian biology and reproductive conditions including infertility, endometriosis, PCOS, and ovarian aging. Its core assets are drug programs — an oral FSH receptor agonist, a JNK inhibitor, AMH-targeting antibodies, and peripherally preferred melatonin receptor agonists — that are advanced through internal R&D and academic collaborations and ultimately licensed or sold to pharmaceutical partners. The company also offers a free consumer-facing fertility insights tool, MyFertility Compass.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • First-in-class oral FSH receptor agonist drug candidate nominated
+2 more records
Product overview1 text field

Celmatix is a women's health biotech company dedicated to translating advances in female biology into novel therapeutics. The company operates multiple drug development programs including: an oral FSH receptor agonist for fertility treatment; a JNK inhibitor for endometriosis; AMH-targeting antibodies for ovarian aging and lifespan extension; and a melatonin receptor agonist program for PCOS and related conditions. The company also offers MyFertility Compass, a free online data analytics tool. Following the March 2026 acquisition by Gedeon Richter, the women's health discovery portfolio including the FSH receptor agonist, JNK inhibitor, and AMH programs is now part of Gedeon Richter's pipeline.

Product and service5 records
1Oral FSH Receptor Agonist Program
CategoryDrug Program — Fertility Therapeutics
Description

First-in-class oral Follicle-Stimulating Hormone (FSH) receptor agonist drug program intended to enable more patient-friendly ovarian stimulation for fertility treatment. Lead compound was nominated in October 2024, and the program was part of the portfolio acquired by Gedeon Richter in March 2026.

2JNK Inhibitor Program (Endometriosis)
CategoryDrug Program — Endometriosis and Related Indications
Description

Novel Jun N-terminal kinase (JNK) inhibitor drug program representing a potential non-hormonal immunotherapy approach for endometriosis targeting both pain and inflammation, with potential expansion to PCOS and ovarian aging. Developed using the DEC-Tec platform at Baylor College of Medicine. Launched January 2025 and part of the portfolio acquired by Gedeon Richter in March 2026.

3AMH-Targeting Antibodies Program
CategoryDrug Program — Ovarian Function / Menopausal Health
Description

Early-stage therapeutic antibody program targeting Anti-Müllerian Hormone (AMH), including both agonists and antagonists, designed to provide control over ovarian folliculogenesis and potentially extend ovarian function throughout a woman's lifespan. Developed with support from a $3.5M ARPA-H award and part of the portfolio acquired by Gedeon Richter in March 2026.

4Melatonin Receptor Agonist Program
CategoryDrug Program — PCOS and Related Women's Health Indications
Description

Drug program targeting peripherally preferred melatonin receptors outside the central nervous system (CNS), initially for PCOS, with potential expansion to endometriosis and menopausal symptoms. Subject of a collaboration and license option agreement with Aché Laboratórios announced in August 2023.

5MyFertility Compass
CategoryDigital Health Tool — Consumer Fertility Analytics
Description

Free online data analytics tool providing fertility-related insights and guidance to individual users, hosted at myfertilitycompass.io as part of Celmatix's consumer-facing digital presence.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-03
Description

Hungarian pharmaceutical company Gedeon Richter acquired Celmatix's women's health discovery portfolio including programs spanning infertility, endometriosis, and ovarian aging. Assets include first-in-class oral FSH receptor agonist, novel JNK inhibitor for endometriosis, and early-stage AMH-targeting antibodies. Celmatix will receive upfront and milestone payments as development progresses.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-08-08
Description

Collaboration and license option agreement with leading Brazilian pharmaceutical company to jointly investigate a novel peripherally preferred melatonin receptor agonist for Women's Health indications, starting with PCOS.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-03-13
Description

Long-term collaboration with researchers from University of Oxford and 24 other institutions on the largest genetic study on endometriosis to date, including DNA from 60,600 women with endometriosis and 701,900 controls. Study published in Nature Genetics.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Five-year multi-target alliance with Evotec for drug discovery. Milestone achieved when Evotec and Bayer AG advanced a second drug program centered around a novel Celmatix-identified drug target into hit-identification.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Drug discovery partnership utilizing the DNA-Encoded Chemistry Technology (DEC-Tec) platform at the Center for Drug Discovery for developing JNK inhibitor therapeutic candidates for endometriosis and other women's health indications.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage women's health biotech focused on reproductive health conditions including endometriosis and preterm labor; directly comparable in therapeutic area, modality class, and B2B pharma-partnering model.

TypeDirect peer
Description

Women's health biotech developing therapies for uterine fibroids, endometriosis, and prostate cancer; directly comparable specialty pharma/Biotech model targeting the same reproductive indications.

TypeDirect peer
Description

Women's health-focused biotech with a portfolio model spanning contraception, fertility, and menopause; directly comparable clinical-stage pipeline structure and pharma-licensing revenue approach.

TypeDirect peer
Description

Women's health company focused on menopause, contraception, and prenatal vitamins with a commercial-stage franchise; comparable therapeutic focus even though TherapeuticsMD has reached commercialization.

TypeBroad incumbent
Description

Large established women's health company spun out of Merck, with a broad franchise in contraception, fertility, and menopause; broader portfolio player but directly relevant comparator for any commercialized women's health asset.

TypeBroad incumbent
Description

Global pharma with leading fertility and reproductive health franchise including Bravelle and Menopur; directly comparable end market and the type of strategic acquirer/licensee relevant to Celmatix's FSH agonist.

TypeBroad incumbent
Description

Hungarian pharma that acquired Celmatix's discovery portfolio in 2026; operates an established women's health and CNS franchise and is the most directly relevant acquirer counterparty for any future Celmatix deal.

8Forendo Pharma
TypeEmerging player
Description

Clinical-stage women's health biotech focused on endometriosis and other gynecological conditions with novel non-hormonal mechanisms; directly comparable early-stage endometriosis pipeline.

TypeEmerging player
Description

Diagnostics company focused on endometriosis biomarkers; partial overlap given Celmatix's endometriosis drug programs and prior genomics work in the same indication.

TypeBroad incumbent
Description

Global pharma with reproductive health and women's health therapeutic franchises including fertility treatments; broad incumbent that competes in the same end markets as Celmatix's pipeline.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Celmatix

Women's Health Therapeutics / Reproductive Health Drug Discoverycelmatix.com

Celmatix is a preclinical-stage women's health biotech developing first-in-class therapeutics for infertility, endometriosis, PCOS, and ovarian aging using the DEC-Tec discovery platform, monetizing its pipeline through licensing, asset sales, and grants.

What Celmatix does

Celmatix is a US-based, preclinical-stage women's health biotechnology company founded in 2009 and headquartered in New York City. It develops novel therapeutics targeting ovarian biology and female reproductive health across four primary indications: infertility, endometriosis, polycystic ovary syndrome (PCOS), and ovarian aging. Its pipeline centers on first-in-class candidates including an oral follicle-stimulating hormone (FSH) receptor agonist for fertility, a Jun N-terminal kinase (JNK) inhibitor for endometriosis pain and inflammation, anti-Müllerian hormone (AMH)-targeting antibodies for ovarian function, and peripherally restricted melatonin receptor agonists for PCOS and related conditions. Discovery leverages the DNA-Encoded Chemistry Technology (DEC-Tec) platform housed at Baylor College of Medicine's Center for Drug Discovery and is informed by the largest published genetic dataset on endometriosis, assembled with the University of Oxford and 24 collaborating institutions.

Celmatix operates as a B2B asset-development biotech rather than a commercial product company. Its revenue model is built on licensing deals, asset sales, and milestone payments from pharmaceutical partners, supplemented by non-dilutive research grants. In March 2026, Gedeon Richter acquired Celmatix's discovery portfolio — encompassing the oral FSH receptor agonist, JNK inhibitor, and AMH antibody programs — in exchange for upfront and milestone payments; Celmatix retained certain residual programs and continues to operate. The company also has a free consumer-facing digital tool, MyFertivity Compass, that provides fertility-related analytics without disclosed monetization. Headcount sits in the 101–250 range, consistent with a preclinical biotech sustaining multiple discovery programs alongside an academic and pharma partnership network that includes Aché Laboratórios, Evotec, and Baylor College of Medicine.

Celmatix firmographics

Firmographics
Name
Celmatix
Legal name
Celmatix Inc.
Website
https://celmatix.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
Celmatix is a preclinical-stage women's health biotech developing first-in-class therapeutics for infertility, endometriosis, PCOS, and ovarian aging using the DEC-Tec discovery platform, monetizing its pipeline through licensing, asset sales, and grants.
Ownership category
akta.pro rank

Celmatix industry classification

Industry
Product category
Women's Health Therapeutics / Reproductive Health Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Women's health therapeutics
  • Fertility drug development
  • Reproductive medicine biotech
  • Endometriosis treatment
  • Ovarian biology research

Where Celmatix is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Celmatix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Licensing and asset sales: Celmatix generates revenue through licensing agreements and asset sales to pharmaceutical companies. In March 2026, Gedeon Richter acquired Celmatix's women's health discovery portfolio including upfront and milestone payments as development progresses.
  2. Research funding and grants: Non-dilutive funding from government agencies such as ARPA-H to support early-stage research efforts in women's health therapeutics.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Celmatix product offering

Product offering

Core offering

Celmatix is a preclinical-stage women's health biotech that discovers and develops novel therapeutics targeting ovarian biology and reproductive conditions including infertility, endometriosis, PCOS, and ovarian aging. Its core assets are drug programs — an oral FSH receptor agonist, a JNK inhibitor, AMH-targeting antibodies, and peripherally preferred melatonin receptor agonists — that are advanced through internal R&D and academic collaborations and ultimately licensed or sold to pharmaceutical partners. The company also offers a free consumer-facing fertility insights tool, MyFertility Compass.

Product overview

Celmatix is a women's health biotech company dedicated to translating advances in female biology into novel therapeutics. The company operates multiple drug development programs including: an oral FSH receptor agonist for fertility treatment; a JNK inhibitor for endometriosis; AMH-targeting antibodies for ovarian aging and lifespan extension; and a melatonin receptor agonist program for PCOS and related conditions. The company also offers MyFertility Compass, a free online data analytics tool. Following the March 2026 acquisition by Gedeon Richter, the women's health discovery portfolio including the FSH receptor agonist, JNK inhibitor, and AMH programs is now part of Gedeon Richter's pipeline.

Differentiator

Problem solved

Functional benefit

Products and services

  • Oral FSH Receptor Agonist Program First-in-class oral Follicle-Stimulating Hormone (FSH) receptor agonist drug program intended to enable more patient-friendly ovarian stimulation for fertility treatment. Lead compound was nominated in October 2024, and the program was part of the portfolio acquired by Gedeon Richter in March 2026.
  • JNK Inhibitor Program (Endometriosis) Novel Jun N-terminal kinase (JNK) inhibitor drug program representing a potential non-hormonal immunotherapy approach for endometriosis targeting both pain and inflammation, with potential expansion to PCOS and ovarian aging. Developed using the DEC-Tec platform at Baylor College of Medicine. Launched January 2025 and part of the portfolio acquired by Gedeon Richter in March 2026.
  • AMH-Targeting Antibodies Program Early-stage therapeutic antibody program targeting Anti-Müllerian Hormone (AMH), including both agonists and antagonists, designed to provide control over ovarian folliculogenesis and potentially extend ovarian function throughout a woman's lifespan. Developed with support from a $3.5M ARPA-H award and part of the portfolio acquired by Gedeon Richter in March 2026.
  • Melatonin Receptor Agonist Program Drug program targeting peripherally preferred melatonin receptors outside the central nervous system (CNS), initially for PCOS, with potential expansion to endometriosis and menopausal symptoms. Subject of a collaboration and license option agreement with Aché Laboratórios announced in August 2023.
  • MyFertility Compass Free online data analytics tool providing fertility-related insights and guidance to individual users, hosted at myfertilitycompass.io as part of Celmatix's consumer-facing digital presence.

Quantifiable outcome

  • First-in-class oral FSH receptor agonist drug candidate nominated
  • +2 more outcomes

Companies that use Celmatix

Customer profile

Segments2 records

Ideal customer profiles2 records

Celmatix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Celmatix partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • Gedeon RichtercoreStrategic or Co-development Partner · 3 March 2026Hungarian pharmaceutical company Gedeon Richter acquired Celmatix's women's health discovery portfolio including programs spanning infertility, endometriosis, and ovarian aging. Assets include first-in-class oral FSH receptor agonist, novel JNK inhibitor for endometriosis, and early-stage AMH-targeting antibodies. Celmatix will receive upfront and milestone payments as development progresses.
  • Aché LaboratórioscoreStrategic or Co-development Partner · 8 August 2023Collaboration and license option agreement with leading Brazilian pharmaceutical company to jointly investigate a novel peripherally preferred melatonin receptor agonist for Women's Health indications, starting with PCOS.
  • University of OxfordcoreStrategic or Co-development Partner · 13 March 2023Long-term collaboration with researchers from University of Oxford and 24 other institutions on the largest genetic study on endometriosis to date, including DNA from 60,600 women with endometriosis and 701,900 controls. Study published in Nature Genetics.
  • EvoteccoreStrategic or Co-development Partner · 1 January 2018Five-year multi-target alliance with Evotec for drug discovery. Milestone achieved when Evotec and Bayer AG advanced a second drug program centered around a novel Celmatix-identified drug target into hit-identification.
  • Baylor College of MedicinecoreStrategic or Co-development PartnerDrug discovery partnership utilizing the DNA-Encoded Chemistry Technology (DEC-Tec) platform at the Center for Drug Discovery for developing JNK inhibitor therapeutic candidates for endometriosis and other women's health indications.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Celmatix competitors and assessment

Company assessment

Direct peers

  • ObsEva: Clinical-stage women's health biotech focused on reproductive health conditions including endometriosis and preterm labor; directly comparable in therapeutic area, modality class, and B2B pharma-partnering model.
  • Myovant Sciences: Women's health biotech developing therapies for uterine fibroids, endometriosis, and prostate cancer; directly comparable specialty pharma/Biotech model targeting the same reproductive indications.
  • Dare Bioscience: Women's health-focused biotech with a portfolio model spanning contraception, fertility, and menopause; directly comparable clinical-stage pipeline structure and pharma-licensing revenue approach.
  • TherapeuticsMD: Women's health company focused on menopause, contraception, and prenatal vitamins with a commercial-stage franchise; comparable therapeutic focus even though TherapeuticsMD has reached commercialization.

Broad incumbents

  • Organon: Large established women's health company spun out of Merck, with a broad franchise in contraception, fertility, and menopause; broader portfolio player but directly relevant comparator for any commercialized women's health asset.
  • Ferring Pharmaceuticals: Global pharma with leading fertility and reproductive health franchise including Bravelle and Menopur; directly comparable end market and the type of strategic acquirer/licensee relevant to Celmatix's FSH agonist.
  • Gedeon Richter: Hungarian pharma that acquired Celmatix's discovery portfolio in 2026; operates an established women's health and CNS franchise and is the most directly relevant acquirer counterparty for any future Celmatix deal.
  • Astellas Pharma: Global pharma with reproductive health and women's health therapeutic franchises including fertility treatments; broad incumbent that competes in the same end markets as Celmatix's pipeline.

Emerging players

  • Forendo Pharma: Clinical-stage women's health biotech focused on endometriosis and other gynecological conditions with novel non-hormonal mechanisms; directly comparable early-stage endometriosis pipeline.
  • DotLab: Diagnostics company focused on endometriosis biomarkers; partial overlap given Celmatix's endometriosis drug programs and prior genomics work in the same indication.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Celmatix social profiles

Digital presence

Celmatix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Celmatix leadership team

Management profile

Number of profiles

Profiles4 records

Celmatix subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Celmatix funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Celmatix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Celmatix

What does Celmatix do?

Celmatix is a preclinical-stage women's health biotech that discovers and develops novel therapeutics targeting ovarian biology and reproductive conditions including infertility, endometriosis, PCOS, and ovarian aging. Its core assets are drug programs — an oral FSH receptor agonist, a JNK inhibitor, AMH-targeting antibodies, and peripherally preferred melatonin receptor agonists — that are advanced through internal R&D and academic collaborations and ultimately licensed or sold to pharmaceutical partners. The company also offers a free consumer-facing fertility insights tool, MyFertility Compass.

Is Celmatix a public or private company?

Celmatix is a private company. It is classified as venture growth investor backed and is currently operating.

When was Celmatix founded?

Celmatix was founded in 2009. It employs 11 to 50 people.

Where is Celmatix based?

Celmatix is headquartered in New York, United States, in the North America region.

How does Celmatix make money?

Two revenue lines are on record. Licensing and asset sales are the primary driver. The others are research funding and grants.

Who are Celmatix's main competitors?

Direct peers on record are ObsEva, Myovant Sciences, Dare Bioscience and TherapeuticsMD. Broad incumbents are Organon, Ferring Pharmaceuticals, Gedeon Richter and Astellas Pharma. Emerging players are Forendo Pharma and DotLab.

Does Celmatix have an API?

No public API is recorded for Celmatix.

What industry is Celmatix in?

Celmatix's product category is Women's Health Therapeutics / Reproductive Health Drug Discovery. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyRichter sharpens ovarian aging focus following Celmatix asset dealHungarian pharmaceutical company Gedeon Richter has acquired the women's health drug discovery portfolio from US biotech Celmatix, adding three early-stage programs spanning fertility, endometriosis, and ovarian aging to its pipeline. Financial terms were not disclosed, though Celmatix will receive upfront and milestone payments as development progresses. The deal signals ovarian biology emerging as an investable area within longevity science, with Richter positioning itself at the intersection of reproductive health and broader healthspan innovation.TracxnTop startups in In Vitro Diagnostics in New York City, United States (Oct, 2025)This article lists top In Vitro Diagnostics startups in New York City, highlighting Celmatix, AcuamarkDx, Lucid Diagnostics, and PAVmed along with their funding stages and key product offerings. The report notes that an average of two new companies in this sector have been launched annually over the past decade. It provides specific details on recent funding rounds and technological capabilities for each listed entity.Business Wire BlogCelmatix Selected to Receive $3.5 Million Award from ARPA-H’s Sprint for Women’s HealthCelmatix Inc. has been selected to receive a $3.5 million award from the Advanced Research Projects Agency for Health (ARPA-H) through its Sprint for Women’s Health initiative. This funding will support the development of a therapeutic aimed at extending and improving ovarian function throughout a woman's lifespan by targeting Anti-Müllerian Hormone (AMH). The project is led by Celmatix executives and aims to address critical unmet challenges in women's health conditions disproportionately affecting women post-menopause.DowntownnyLearn About BioTech and the Future of Healthcare at LM Live’s First Event of the SeasonWomen.NYC and the Downtown Alliance are hosting a panel event titled "Unlocking Careers of the Future: Women in BioTech" on October 24 at the Studio at 7 WTC. The event features industry leaders from BioHarmony Therapeutics, Celmatix, and Digital Health New York discussing career pathways and innovations in biotechnology. It is designed to provide networking opportunities for professionals interested in pivoting to or learning more about the healthcare sector.BioSpaceCelmatix Launches Novel PCOS Drug ProgramCelmatix announced a new drug program targeting melatonin receptors outside the central nervous system, aiming to treat PCOS and potentially endometriosis and menopausal symptoms. The company's research found rare functional mutations in melatonin receptor genes in PCOS women, and the program seeks a peripherally-preferred agonist to avoid drowsiness.diginomicaThree ways women are making a difference in dataConfluent's Stephanie Buscemi highlights the critical role of women in data and AI, emphasizing their contributions to closing the gender gap, advocating for diversity, and driving innovation. The article notes that while women currently hold only 26% of data and AI positions, their inclusion is linked to improved business performance and reduced algorithmic bias. It cites specific examples of female-led initiatives and companies like Celematix leveraging data to address previously overlooked health needs.FortuneThis biotech startup thinks it can delay menopause by 15 years. That would transform women’s livesCelmatix, founded by Piraye Beim, is developing a drug to slow ovarian reserve depletion and delay menopause by 10-15 years. The company plans clinical trials in 2023 on women undergoing chemotherapy, aiming to shift menopause age from 50 to 60 or 70.CNBCFertility start-up Celmatix sues former business partner 23andMe for $100 million in damagesCelmatix sued 23andMe in New York's Supreme Court, seeking over $100 million in damages for breaching a 2015 research contract. The lawsuit alleges 23andMe terminated the deal and pressured Celmatix's financing, causing Celmatix to suspend its fertility test Fertilome and lay off staff.Forbes3 Analytics Startups Transforming HealthcareThree healthcare analytics startups—Zebra Medical Vision, Celmatix, and Lumme Labs—are transforming medical imaging, fertility, and addiction care. Zebra's AI detects fractures and blockages for $1 per scan, Celmatix's Polaris predicts fertility success, and Lumme's smartwatch detects smoking gestures with 95% accuracy. All aim to augment rather than replace doctors.PrwebCelmatix Biosciences Launches Search for Next-Generation Oral ContraceptivesCelmatix announced an exploratory initiative to use its genomics platform to identify novel targets for next-generation oral contraceptives, supported by the Bill & Melinda Gates Foundation. The company aims to develop non-hormonal approaches with reduced side effects, addressing unmet needs among over 225 million women in low- and middle-income countries.